Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest 2025 Sep 02;135(17)
Date
07/01/2025Pubmed ID
40591420Pubmed Central ID
PMC12404765DOI
10.1172/JCI188530Scopus ID
2-s2.0-105015178992 (requires institutional sign-in at Scopus site) 1 CitationAbstract
People with generalized pustular psoriasis experience underlying skin inflammation, even in the absence of flares. Spesolimab treatment helps control the inflammation and prevent future flares.
Author List
Krueger JG, Sarkar MK, Lebwohl MG, Morita A, Gordon K, Bogle R, Cole C, Coon A, Langley RG, Warren RB, Mostaghimi A, Strober B, Burden AD, Zheng M, Mangold AR, Anadkat MJ, Barker JN, Merola JF, Tsoi LC, Tang M, Becker K, Delic D, Thoma C, Gudjonsson JEAuthor
Kenneth Brian Gordon MD Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antibodies, Monoclonal, HumanizedFemale
Humans
Inflammation
Male
Middle Aged
Psoriasis
Receptors, Interleukin
